Home › Upcoming votes › Theriva Biologics, Inc.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Theriva Biologics, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Authorized Common Stock Increase Proposal | Board | For | — |
| 2 | To ratify and confirm | Board | For | — |
| 3 | To approve the adjournment Adjournment |
Board | For | — |
From Theriva Biologics, Inc.’s Form 8-K, filed September 4, 2025, for the meeting held August 29, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Jeffrey J. Kraws | 87% | — |
| Elect Director: Steven A. Shallcross | 87% | — |
| Elect Director: John Monahan | 87% | — |
| Elect Director: Jeffrey Wolf | 87% | — |
| 2. Auditor Ratification Proposal | 92% | Approved |
| 3. Amendment to the Company's 2020 Stock Incentive Plan | 65% | Approved |
| 4. Advisory Vote on the Approval of Executive Compensation | 79% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.